Metabolomic screening of pre-diagnostic serum samples identifies association between alpha- and gamma-tocopherols and glioblastoma riskVisa övriga samt affilieringar
2016 (Engelska)Ingår i: Oncotarget, E-ISSN 1949-2553, Vol. 7, nr 24, s. 37043-37053Artikel i tidskrift (Refereegranskat) Published
Resurstyp
Text
Abstract [en]
Glioblastoma is associated with poor prognosis with a median survival of one year. High doses of ionizing radiation is the only established exogenous risk factor. To explore new potential biological risk factors for glioblastoma, we investigated alterations in metabolite concentrations in pre-diagnosed serum samples from glioblastoma patients diagnosed up to 22 years after sample collection, and undiseased controls. The study points out a latent biomarker for future glioblastoma consisting of nine metabolites (gamma-tocopherol, alpha-tocopherol, erythritol, erythronic acid, myo-inositol, cystine, 2-keto-L-gluconic acid, hypoxanthine and xanthine) involved in antioxidant metabolism. We detected significantly higher serum concentrations of alpha-tocopherol (p=0.0018) and gamma-tocopherol (p=0.0009) in future glioblastoma cases. Compared to their matched controls, the cases showed a significant average fold increase of alpha- and gamma-tocopherol levels: 1.2 for alpha-T (p=0.018) and 1.6 for gamma-T (p=0.003). These tocopherol levels were associated with a glioblastoma odds ratio of 1.7 (alpha-T, 95% CI: 1.0-3.0) and 2.1 (gamma-T, 95% CI: 1.2-3.8). Our exploratory metabolomics study detected elevated serum levels of a panel of molecules with antioxidant properties as well as oxidative stress generated compounds. Additional studies are necessary to confirm the association between the observed serum metabolite pattern and future glioblastoma development.
Ort, förlag, år, upplaga, sidor
2016. Vol. 7, nr 24, s. 37043-37053
Nyckelord [en]
population-based, serum metabolite, vitamin E, antioxidants, brain tumor
Nationell ämneskategori
Cancer och onkologi
Identifikatorer
URN: urn:nbn:se:umu:diva-123973DOI: 10.18632/oncotarget.9242ISI: 000377756800119Scopus ID: 2-s2.0-84978173673OAI: oai:DiVA.org:umu-123973DiVA, id: diva2:1046899
2016-11-152016-07-072024-01-17Bibliografiskt granskad